The revenue versus their compensation feels criminal with a callous disregard for the shareholders money. A small company should be pushing for cashflow from customer receipts and not burdened by executive compensation.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
